View in EDS HTML Full Text PDF Full Text

Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).

Saved in:
Bibliographic Details
Title: Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Authors: Strober B; Department of Dermatology, Yale University, New Haven, Connecticut, USA.; Central Connecticut Dermatology Research, Cromwell, Connecticut, USA., Blauvelt A; Oregon Medical Research Center, Portland, Oregon, USA., Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.; Manchester NIHR Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Papp KA; Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Armstrong AW; Department of Dermatology, University of California Los Angeles, Los Angeles, California, USA., Gordon KB; Dermatology - Froedtert Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Morita A; Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Alexis AF; Department of Dermatology, Weill Cornell Medicine, New York, New York, USA., Lebwohl M; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Foley P; Skin Health Institute and Probity Medical Research, Melbourne, Victoria, Australia., Kisa RM; Bristol Myers Squibb, Princeton, New Jersey, USA., Colston E; Bristol Myers Squibb, Princeton, New Jersey, USA., Wang T; Bristol Myers Squibb, Princeton, New Jersey, USA., Banerjee S; Bristol Myers Squibb, Princeton, New Jersey, USA., Thaçi D; Institute and Comprehensive Centre for Inflammation Medicine, University of Luebeck, Luebeck, Germany.
Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Aug; Vol. 38 (8), pp. 1543-1554. Date of Electronic Publication: 2024 Mar 07.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38451052
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Strober+B%22">Strober B</searchLink>; Department of Dermatology, Yale University, New Haven, Connecticut, USA.; Central Connecticut Dermatology Research, Cromwell, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Blauvelt+A%22">Blauvelt A</searchLink>; Oregon Medical Research Center, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Warren+RB%22">Warren RB</searchLink>; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.; Manchester NIHR Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Papp+KA%22">Papp KA</searchLink>; Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Armstrong+AW%22">Armstrong AW</searchLink>; Department of Dermatology, University of California Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Gordon+KB%22">Gordon KB</searchLink>; Dermatology - Froedtert Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.<br /><searchLink fieldCode="AU" term="%22Morita+A%22">Morita A</searchLink>; Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Alexis+AF%22">Alexis AF</searchLink>; Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Lebwohl+M%22">Lebwohl M</searchLink>; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Foley+P%22">Foley P</searchLink>; Skin Health Institute and Probity Medical Research, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Kisa+RM%22">Kisa RM</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Colston+E%22">Colston E</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Wang+T%22">Wang T</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Banerjee+S%22">Banerjee S</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Thaçi+D%22">Thaçi D</searchLink>; Institute and Comprehensive Centre for Inflammation Medicine, University of Luebeck, Luebeck, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229216037%22">Journal of the European Academy of Dermatology and Venereology : JEADV</searchLink> [J Eur Acad Dermatol Venereol] 2024 Aug; Vol. 38 (8), pp. 1543-1554. <i>Date of Electronic Publication: </i>2024 Mar 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9216037 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1468-3083 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209269959%22">09269959 </searchLink><i>NLM ISO Abbreviation: </i>J Eur Acad Dermatol Venereol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38451052
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/jdv.19925
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1543
    Titles:
      – TitleFull: Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Strober B
      – PersonEntity:
          Name:
            NameFull: Blauvelt A
      – PersonEntity:
          Name:
            NameFull: Warren RB
      – PersonEntity:
          Name:
            NameFull: Papp KA
      – PersonEntity:
          Name:
            NameFull: Armstrong AW
      – PersonEntity:
          Name:
            NameFull: Gordon KB
      – PersonEntity:
          Name:
            NameFull: Morita A
      – PersonEntity:
          Name:
            NameFull: Alexis AF
      – PersonEntity:
          Name:
            NameFull: Lebwohl M
      – PersonEntity:
          Name:
            NameFull: Foley P
      – PersonEntity:
          Name:
            NameFull: Kisa RM
      – PersonEntity:
          Name:
            NameFull: Colston E
      – PersonEntity:
          Name:
            NameFull: Wang T
      – PersonEntity:
          Name:
            NameFull: Banerjee S
      – PersonEntity:
          Name:
            NameFull: Thaçi D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2024 Aug
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1468-3083
          Numbering:
            – Type: volume
              Value: 38
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Journal of the European Academy of Dermatology and Venereology : JEADV
              Type: main
ResultId 1